All In Biotech

Drug Trial Radar · NCT01697319

Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation

A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation

Last checked: Nov 20, 2026Latest source record: Jan 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

16

Actual

Start

Aug 2012

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Oct 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.

Conditions

  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

Interventions

  • BMN 110Drug

    Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Speed as Measured in Functional Dexterity Test (FDT)Time frame: Up to 96 weeks
  2. Change From Baseline in Strength as Assessed by Grip and Pinch Test (GPT)Time frame: Up to 96 weeks
  3. Percent Change From Baseline in Speed as Measured in Timed 25-Foot Walk Test (25FWT)Time frame: Up to 96 weeks

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Universitätsklinikum Hamburg

    Hamburg, Germany

  • University Medical Center Mainz, Center of Pediatric and Adolescent Medicine Villa Metabolica

    Mainz, Germany

  • NIHR/Wellcome Trust Birmingham CRF, Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Central Manchester University Hospitals NHS Foundation Trust

    Manchester, United Kingdom

  • Salford Royal NHS Foundation Trust

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.